High-Volume Online Haemodiafiltration was lively discussed during a recent Scientific Forum held by Fresenius Medical Care Singapore. The event was supported by the Singapore Society of Nephrology and due to its high scientific quality it has been submitted to the Singapore Medical Council for CME accreditation. Local nephrologists and key opinion leaders reviewed the current study data towards patient outcomes. Read further for an overview of the meeting outcomes.
Taking best care of our patients by providing innovative and high quality treatment in a friendly and safe environment is at the forefront of our efforts. Here we describe how our Fresenius Medical Care GDI clinic is setting now a new standard in renal care.
PatientOnLine (POL) is a therapy management tool that allows prescriptions to be individually adjusted according to the needs of patients undergoing peritoneal dialysis (PD). Here we provide an overview of clinical data supporting its use.
PatientOnLine (POL) is a powerful therapy management tool that supports clinical decision making by bringing together all components needed to deliver a high quality peritoneal dialysis (PD) treatment. Read here how POL has evolved based on clinicians feedback over time and how it can support you in your daily practice.
High-Volume HDF improves patient survival
The Catalonian Online Haemodiafiltration Survival Study (ESHOL) published in February 2013 confirms Fresenius Medical Care’s conviction that every patient should be given the chance to benefit from haemodiafiltration (HDF) therapy with high volumes of substitution fluid (HighVolumeHDF). The primary outcome of the study was that HighVolumeHDF therapy significantly improves patient survival compared with conventional dialysis treatment. At this year’s ERA-EDTA Congress, HighVolumeHDF was the main focus of Fresenius Medical Care’s activities.